By Eddie Beaver
An appeals court upheld on Tuesday findings by a competition tribunal that a group of pharmaceutical companies abused its dominant position to overcharge for a life-saving adrenal drug, but sent approximately £100 million ($133 million) in penalties back for reconsideration.
Read Full Article